Antidotes for factor Xa inhibitors and methods of using the same

POLYMER FACTOR IX MOIETY CONJUGATES

Methods for preparing factor X, activated factor X, inactivated factor X and inactivated factor Xa, and pharmaceutical compositions comprising same

Excipients for use in adeno-associated virus pharmaceutical formulations, and pharmaceutical formulations made therewith

COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION

USE OF RAPAMYCIN TO INHIBIT IMMUNE RESPONSE AND INDUCE TOLERANCE TO GENE THERAPY VECTOR AND ENCODED TRANSGENE PRODUCTS

Albumin Fusion Proteins

USE OF COAGULATION PROTEINS TO LYSE CLOTS

Liquid, Aqueous Pharmaceutical Composition of Factor VII Polypeptides

Composition of biocompatible microparticles of alginic acid for the controlled release of active ingredients by intravenous administration

POLYMER FACTOR IX MOIETY CONJUGATES

METHODS AND COMPOSITIONS FOR INTRA-ARTICULAR COAGULATION PROTEINS

POLYMER FACTOR IX MOIETY CONJUGATES

POLYMER FACTOR IX MOIETY CONJUGATES

Antidotes for factor Xa inhibitors and methods of using the same in combination with blood coagulating agents

Hemophilia Treatment by Inhalation of Coagulation Factors

Polymer-factor IX moiety conjugates

METHODS OF DIAGNOSING, TREATING, AND PREVENTING INCREASED VASCULAR PERMEABILITY

MODIFIED BLOOD FACTORS COMPRISING A LOW DEGREE OF WATER SOLUBLE POLYMER

Humanized Viral Vectors and Methods of Use Thereof

Synergistic therapeutic use of Prothrombin Complex Concentrates with FVIII concentrates

METHODS OF MAKING CONCENTRATED FIBRINOGEN- AND PLATELET-CONTAINING COMPOSITIONS

Glycopegylated factor IX

Use of Factor VIIa or Factor VIIa equivalents for treating late complications of trauma

Liquid, aqueous pharmaceutical compositions of factor VII polypeptides

MODIFIED PROTEINS

Analgesic and anti-inflammatory composition

Glycopegylation methods and proteins/peptides produced by the methods

GLYCEROL LINKED PEGYLATED SUGARS AND GLYCOPEPTIDES

Use of human cells of myeloid leukaemia origin for expression of antibodies

Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide

Biologic devices for hemostasis

Modified coagulation factor VIIa with extended half-life

Albumin Fusion Proteins

Method for Producing Factor VII Glycoforms

Polymer-Factor IX Moiety Conjugates

Methods for treating bleeding disorders using sulfated polysaccharides

METHOD AND PRODUCT FOR LOCATING AN INTERNAL BLEEDING SITE

Pegylated factor VII glycoforms

Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor

Use of Factor VII Polypeptides for Neuroprotection

ISOLATED STROMAL CELLS FOR USE IN THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM

Use of Factor VIIa Analogues with Increased Activity

Use of factor VIIa analogues with increased activity

Stabilised compositions of factor VII polypeptides

Compositions and methods for modulating hemostasis

Use of Factor VIIa or Factor VIIa Equivalents for Preventing or Attenuating Haemorrhage Growth, and/or Oedema Generation Following Intracerebral Haemorrhage (ICH) in Patients Treated with Antiplatelet Therapy

Dried blood factor composition comprising trehalose

Pharmaceutical Preparations And Medicines Capable Of Generating, And/Or Containing, Thrombin

Extracellular histones as biomarkers for prognosis and molecular targets for therapy

Human Coagulation Factor VII Polypeptides

Antidotes for factor Xa inhibitors and methods of using the same

Methods for local treatment with factor VII

GLYCOPEGYLATED FACTOR IX

Method of the invention preparations of factor IXa

Use of Factor VIIa for the Treatment of Burn Trauma

Materials and methods for the detection of nitrated fibrinogen

Use of Factor VIIa or Factor VIIa Equivalents for Treating Trauma

LIQUID FACTOR VII COMPOSITION

Thrombin-free biological adhesive and use thereof as a medicament

USE OF ACTIVATED COAGULATION FACTOR VII FOR TREATING THROMBOLYTIC THERAPY-INDUCED MAJOR BLEEDINGS

COMBINATION THERAPY WITH A COMPOUND ACTING AS A PLATELET ADP RECEPTOR INHIBITOR

Albumin Fusion Proteins

Albumin Fusion Proteins

Albumin Fusion Proteins

Albumin fusion proteins

Albumin Fusion Proteins

Single-dose administration of Factor VIIa

Albumin Fusion Proteins

Glycopegylated Factor Ix

Factor VIIa-polysialic acid conjugate having prolonged in vivo half-life

Methods and compositions for use in gene therapy for treatment of hemophilia

Closed container comprising an activated factor VII polypeptide, processes for the preparation of the same, and a kit and a method for use of the kit

Conjugates of a Polymer and a Protein Linked by an Oxime Group

Methods For Treating Bleeding

GLYCEROL LINKED PEGYLATED SUGARS AND GLYCOPEPTIDES

PRODUCTION OF A BIOLOGICAL FACTOR AND CREATION OF AN IMMUNOLOGICALLY PRIVILEGED ENVIRONMENT USING GENETICALLY ALTERED SERTOLI CELLS

Albumin fusion proteins

Pharmaceutical Composition Comprising Factor VII Polypeptides and Protein C Inhibitors

USE OF RAPAMYCIN TO INHIBIT RESPONSE AND INDUCE TOLERANCE TO GENE THERAPY VECTOR AND ENCODED TRANSGENE PRODUCTS

Combined Use of Factor VII Polypeptides and Factor VIII Polypeptides

Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor

Adeno-associated virus (AAV) serotype 8 sequences, vectors containing the same, and uses therefor

Combined Use of Factor VII Polypeptides and Factor IX Polypeptides

Pharmaceutical Composition Comprising Factor VII Polypeptides And Thrombomodulin Polypeptides

Pharmaceutical Composition Comprising Factor VII Polypeptides and TAFI Polypeptides

Pharmaceutical Compositions Comprising Factor VII Polypeptides and Factor XI Polypeptides

Pharmaceutical Composition Comprising Factor VII Polypeptides and Protein S Inhibitors

Pegylated Factor VII Glycoforms

Modified vitamin K-dependent polypeptides

DIAFILTRATION SYSTEM TO FRACTIONATE PROTEIN MIXTURES

AAV virions with decreased immunoreactivity and uses therefor

Modified vitamin K-dependent polypeptides

Albumin fusion proteins

PHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIa AND A FACTOR XIII

Method for treating blood coagulation disorders

Compositions of less immunogenic and long-circulating protein-lipid complexes

Multifunctional blood substitute

Methods for treating local tracheal, bronchial or alveolar bleeding or hemoptysis

Use of factor VIIa or factor VIIa equivalents for preventing or attenuating haemorrhage growth, and/or oedema generation following intracerebral haemorrhage

Genetic modification of the lung as a portal for gene delivery

Methods for Modifying Cell Motility Using Factor VIIa Antagonist

Stabilized preparations of serine endopeptidases, their preparation and use

Modified vitamin K-dependent polypeptides

Modified vitamin K-dependent polypeptides

Pharmaceutical Composition Comprising Factor VII Polypeptides and PAI-1 Polypeptide

Nucleic acid formulations for gene delivery and methods of use

Stabilised solid compositions of factor VII polypeptides

METHOD OF MODULATING VASCULARIZATION

Compositions and methods for locating an internal bleeding site

Induction of tolerance by oral administration of factor VIII and treatment of hemophilia

Pharmaceutical composition comprising proteins and/or polypeptides and colloidal particles

Modified vitamin K. dependent polypeptides

Haemostatic sprays and compositions

Use of cathepsin s inhibitors for treating an immune response caused by administration of a small molecule therapeutic or biologic

Sodium chloride solution for drug reconstitution or dilution

Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination

Factor VII glycoforms

FVII or FVIIa Gla domain variants

One pot desialylation and glycopegylation of therapeutic peptides

Use of factor VIIa or factor VIIa equivalents for treating trauma

Uses of factor VIIa or factor VIIa equivalents for treating late complications of trauma

Modified vitamin K-dependent polypeptides

Methods for preventing and treating local tracheal, bronchial or alveolar bleeding or hemoptysis

FVII or FVIIa variants

Novel compounds

Composition and method for the repair and regeneration of cartilage and other tissues

Stimulators of Factor X activated (FXa) as new topical antihemorrhagic agents

Pharmaceutical compositions comprising factor VII polypeptides and factor XI polypeptides

Glycopegylation methods and proteins/peptides produced by the methods

Coagulation proteins, coagulation-anticoagulation protein complexes, derivatives thereof and their uses

Stabilised compositions of Factor VII

Method for treating Hemophilia B

Pharmaceutical composition comprising a factor VII polypeptide and epsilon-aminocaproic acid

Combined use of factor VII polypeptides and factor VIII polypeptides

Use of coagulation proteins to lyse clots

Modified vitamin K-dependent polypeptides

FVII OR FVIIa GLA DOMAIN VARIANTS

Factor VII or Factor VIIa Gla domain variants

Factor V11 or factor V11A GLA domain variants

Agent neutralizint tissue factor inhibitor and agent neutralizing activated blood coagulation factor viii preparation

Combined use of factor VII polypeptides and factor IX polypeptides

Liquid, aqueous pharmaceutical compositions of factor VII polypeptides

Pharmaceutical composition comprising a factor VIIa and a factor XIII

Analgesic and anti-inflammatory composition

Nucleic acids encoding human coagulation Factor VII polypeptides

Liquid, aqueous pharmaceutical composition of Factor VII polypeptides

Fvii or fviia variants having increased clotting activity

Protein stabilization in solution

Method of providing hemostasis to a wound

Novel formulations

Activators and inhibitors of protease activated receptor2 (PAR2) and methods of use

Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products

Liquid, aqueous, pharmaceutical compositions of factor VII polypeptides

Polymer-factor IX moiety conjugates

Compositions of oral gene therapy and methods of using same

AAV virions with decreased immunoreactivity and uses therefor

Glycopegylated factor IX

Use of TF antagonists

Pharmaceutical composition comprising factor VII polypeptide and PAI-1 polypeptide

Composition and method for the repair and regeneration of cartilage and other tissues

Method and product for locating an internal bleeding site

Use of factor VIIa or factor VIIa equivalents for preventing or attenuating haemorrhage growth, and/or oedema generation following intracerebral haemorrhage

Pharmaceutical composition comprising factor VII polypeptides and protein C inhibitors

Methods for treating bleeding disorders using sulfated polysaccharides

Pharmaceutical composition comprising factor VII polypeptides and tranexamic acid

Albumin fusion proteins

Albumin fusion proteins

Pharmaceutical composition comprising factor VII polypeptides and tissue plasminogen inhibitors

Methods for treating an ischemic disorder and improving stroke outcome

Methods for modifying cell motility using factor VIIa antagonist

Nitrated fibrinogen as a marker for coronary artery disease and rapid blood clot formation

Factor IXa for the treatment of bleeding disorders

Pharmaceutical preparations and medicine capable of generating and/or containing thrombin

Therapeutic use of factor XI

FVII or FVIIa Gla domain variants

Clotting factor-Fc chimeric proteins to treat hemophilia

Pegylated factor VII glycoforms

Factor VII glycoforms

Methods for treating ischemic disorders using carbon monoxide

Factor VII polypeptides for preventing formation of inhibitors in subjects with haemophilia

Hemophilia treatment by inhalation of coagulation factors

Use of B7-H3 as an immunoregulatory agent

Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B

Method of purifying factor VII and/or factor VIIa